| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
University Hospital Inselspital, Berne University of Bern |
| Information provided by: | University Hospital Inselspital, Berne |
| ClinicalTrials.gov Identifier: | NCT00563940 |
Purpose
Diabetic macular edema is a common complication of ocular diabetes mellitus and can cause blindness. Hypoxygenation of the retina stimulates tissue mediators, especially different subtypes of vascular endothelial growth factor (VEGF). VEGF is responsible for proliferation, extension and increased permeability of the vessels. The aim of our study was to examine the short-term effect of intravitreal bevacizumab (Avastin® 1.25 mg in 0.05 ml) and triamcinolone on visual acuity and central retinal thickness in patients with clinically significant diabetic macular edema (CSME).
| Condition |
|
Diabetic Macular Edema |
| Genetics Home Reference related topics: | X-linked juvenile retinoschisis |
| MedlinePlus related topics: | Edema |
| ChemIDplus related topics: | Bevacizumab |
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | Short-Term Effects of Intravitreal Bevacizumab and Trimacinolone in Patients With Diabetic Macular Edema |
| Estimated Enrollment: | 30 |
| Study Start Date: | March 2007 |
| Estimated Study Completion Date: | March 2008 |
| Groups/Cohorts |
| 1 |
| 2 |
Eligibility
| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients with clinical significant macular edema
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Switzerland | |||||
| Klinik und Poliklinik für Augenheilkunde | |||||
| Bern, Switzerland | |||||
| University Hospital Inselspital, Berne |
| University of Bern |
| Principal Investigator: | Ute Wolf-Schnurrbusch, MD | University of Bern |
| Study Director: | Sebastian Wolf, MD PhD | University of Bern |
More Information
| Study ID Numbers: | AUG 044/07, KEK E: 29-03-07 |
| First Received: | November 26, 2007 |
| Last Updated: | December 5, 2007 |
| ClinicalTrials.gov Identifier: | NCT00563940 |
| Health Authority: | Switzerland: Ethikkommision |
|
|
|
|
|
|
